A great Aussie breakthrough - why ResApp (ASX: RAP) is a A$200m company

Stuart Roberts

Everyone complains that with Life Sciences companies it takes at least ten years of your life and hundreds of millions of dollars to get to a marketable product. In many cases, however, that claim is no longer true, thanks in good measure to smartphones and the Internet. Consider the case of ResApp Health, a Perth-based company developing a smartphone-based diagnostic for respiratory disease. The technology, originally developed at the University of Queensland, can detect, through the measurement of coughs and breathing sounds, a range of respiratory disorders including pneumonia, asthma, and COPD with sensitivities and specificities greater than 90% and improving all the time thanks to machine learning. The technology works on existing smartphones with no extra specialised hardware required, making rapid deployment post-regulatory approval a relatively straightforward and highly scalable proposition. ResApp Health is now preparing for a registration study of the technology, ahead of a filing for FDA approval expected in early 2017. That's right - around six months from now we could be talking about ResApp having a product to sell. Learn more at (VIEW LINK)


Stuart Roberts

By background I am an investment professional who did Australian equity research from the late 1990s until 2015. For a lot of that time I focused on healthcare and biotechnology, and the Life Sciences has become a passion of mine. My forte is...

Expertise

Comments

Please sign in to comment on this wire.